Clinical Trial

Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics

Study acronym: KING
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
the investigators hypothesise that 18F-FDOPA PET kinetic parameters are good biomarkers to characterise suspected LGG brain lesions that exhibit no contrast on MRI, for identifying aggressive lesions. These parameters could constitute diagnostic biomarkers for this indication. This new diagnostic tool could enhance patient care in the short term in an evolving pathology affecting socially active subjects with a poor prognosis
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-22; most recent amendment 2024-09-13.
Status change: Not Yet Recruiting → Recruiting 2023-07-03
Trial Details
NCT Number NCT05512403
Lead Sponsor Central Hospital, Nancy, France
Conditions Glioma
Enrollment 88 participants
Start Date 2023-06-13
Primary Completion 2025-12-12 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19